Additional file 1: of Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Figure S1. Confirmation of silencing of BMX, NRTK2, and PDPK1 mediated by siRNA (set 1- #1) knockdown. A) Expression level of BMX, NRTK2 and PDPK1 in in MiaPaCa2, Panc-1, and Nor-P1 cells when scramble siRNA or anti- BMX, NRTK2 and PDPK1 siRNA (set 1- #1) are present. B) Protein level of BMX, NRTK2 and PDPK1 of the three cell lines in immunoblotting. C) anti-BMX, NRTK2 and PDPK1 siRNA (set 2- #2) leads to increased sensitivity to gemcitabine compared to cells with intact BMX, NRTK2 and PDPK1. Full drug response curves in MiaPaCa2, Panc-1, and Nor-P1 cells including cells transfected with scramble siRNA and indicated target siRNAs (set 2- #2) are shown. (PPTX 652Â kb